James Largent - Alimera Sciences Independent Director

ALIM Stock  USD 3.68  0.01  0.27%   

Director

Mr. James R. Largent is Lead Independent Director of the company. He was an Independent Director of Alimera Sciences, Inc. Mr. Largent has worked extensively within the medical industry. He most recently served as a medical and pharmaceutical consultant, including work with U.S. ophthalmic device company, Eyeonics Inc. Also in his role as a consultant, he assisted a multinational pharmaceutical and medical device company in the evaluation of strategic targets. Prior to this, Mr. Largent served in various senior management positions at Allergan, Inc., including as vice president of strategic planning where he fostered licensing deals to build product pipelines. Earlier in his career, he was vice president of strategic marketing at Allergan Medical Optics, Inc. Mr. Largent also held positions of increasing responsibility in the marketing and sales departments at Allergan and Pharmacia Ophthalmics. In addition to serving on our board of directors, Mr. Largent is on the board of directors of Tear Science, Inc., a privately held developer of diagnostic and therapeutic devices for the treatment of patients with dry eye disease since 2018.
Age 67
Tenure 6 years
Professional MarksMBA
Address 6310 Town Square, Alpharetta, GA, United States, 30005
Phone678 990 5740
Webhttps://alimerasciences.com
Largent earned a B.A. in chemistry and an M.B.A., both from the University of California, Irvine. Our board of directors believes that Mr. Largent should serve as a director of the Company, in light of its business and structure, because Mr. Largent has over 30 years of experience in pharmaceutical and medical devices, including the role of vice president of strategic marketing and as a leading industry consultant.

Alimera Sciences Management Efficiency

The company has return on total asset (ROA) of (0.0123) % which means that it has lost $0.0123 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5876) %, meaning that it created substantial loss on money invested by shareholders. Alimera Sciences' management efficiency ratios could be used to measure how well Alimera Sciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of May 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Alimera Sciences' Asset Turnover is very stable compared to the past year.
The company currently holds 67.4 M in liabilities. Alimera Sciences has a current ratio of 1.27, suggesting that it is in a questionable position to pay out its financial obligations when due. Debt can assist Alimera Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Alimera Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alimera Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alimera to invest in growth at high rates of return. When we think about Alimera Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Jon HuntsmanChevron Corp
60
Linnet DeilyChevron Corp
72
Wanda AustinChevron Corp
65
Pamela CraigWalmart
60
Enrique HernandezChevron Corp
64
Ronald SugarAmgen Inc
69
Stacy BrownPhilpotHP Inc
45
Timothy FlynnWalmart
64
Aida AlvarezWalmart
65
Kevin SystromWalmart
32
ron SugarChevron Corp
66
Ronald SugarChevron Corp
72
Tyler JacksAmgen Inc
57
Cesar CondeWalmart
47
Charles MoormanChevron Corp
68
Sanders WilliamsAmgen Inc
69
Robert MiltonAir Lease
60
Carl BassHP Inc
58
Vance CoffmanAmgen Inc
71
Robson WaltonWalmart
73
Rajiv GuptaHP Inc
69
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 145 people. Alimera Sciences (ALIM) is traded on NASDAQ Exchange in USA. It is located in 6310 Town Square, Alpharetta, GA, United States, 30005 and employs 154 people. Alimera Sciences is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Alimera Sciences Leadership Team

Elected by the shareholders, the Alimera Sciences' board of directors comprises two types of representatives: Alimera Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alimera. The board's role is to monitor Alimera Sciences' management team and ensure that shareholders' interests are well served. Alimera Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alimera Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
John Snisarenko, Director
Christopher Visick, General VP
Todd Wood, President Operations
James Largent, Independent Director
Peter Pizzo, Independent Director
Calvin Roberts, Independent Director
Samer Kaba, Chief Medical Officer
Mary Szela, Director
Phil Jones, CFO
Elliot CPA, CFO Treasurer
David Burke, Vice President
Philip Ashman, Sr. VP and European Managing Director
Jason Werner, Chief Officer
David Holland, Co-Founder and Sr. VP of Sales and Marketing
Garheng Kong, Independent Director
Kenneth Green, Chief Scientific Officer and Sr. VP
Richard Eiswirth, Pres and CFO
Brian Halak, Independent Director
Daniel Myers, President CEO, Director
Charles Myers, NonEx Consultant
Mark Brooks, Independent Director
Rich Cockrell, President
David MD, Chief Specialist

Alimera Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alimera Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alimera Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alimera Sciences' short interest history, or implied volatility extrapolated from Alimera Sciences options trading.

Pair Trading with Alimera Sciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alimera Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alimera Sciences will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Alimera Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alimera Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alimera Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alimera Sciences to buy it.
The correlation of Alimera Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alimera Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alimera Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alimera Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alimera Sciences is a strong investment it is important to analyze Alimera Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alimera Sciences' future performance. For an informed investment choice regarding Alimera Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Alimera Stock analysis

When running Alimera Sciences' price analysis, check to measure Alimera Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alimera Sciences is operating at the current time. Most of Alimera Sciences' value examination focuses on studying past and present price action to predict the probability of Alimera Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alimera Sciences' price. Additionally, you may evaluate how the addition of Alimera Sciences to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Alimera Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alimera Sciences. If investors know Alimera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alimera Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.84)
Revenue Per Share
3.159
Quarterly Revenue Growth
0.875
Return On Assets
(0.01)
Return On Equity
(1.59)
The market value of Alimera Sciences is measured differently than its book value, which is the value of Alimera that is recorded on the company's balance sheet. Investors also form their own opinion of Alimera Sciences' value that differs from its market value or its book value, called intrinsic value, which is Alimera Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alimera Sciences' market value can be influenced by many factors that don't directly affect Alimera Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alimera Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alimera Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alimera Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.